Scientific Reports,
Journal Year:
2025,
Volume and Issue:
15(1)
Published: March 27, 2025
The
development
of
innovative
antitumor
formulations
that
are
able
to
increase
the
mortality
cancer
cells
while
decreasing
efficacious
pharmacological
dosage
is
a
fundamental
goal
modern
oncological
research.
In
this
study
paclitaxel
(PTX)-nanomedicine
was
tested
on
two
lines
human
high-grade
serous
ovarian
carcinoma
(hHGS-OC).
Zein,
vegetal
protein,
employed
obtain
nanoparticles
containing
lipophilic
compound
(NanoPTX)
characterized
by
mean
diameter
160
nm,
narrow
size
distribution,
negative
zeta
potential
and
prolonged
release
drug
over
time.
NanoPTX
HEY
COV362
demonstrating
an
apoptosis,
particularly
papillary
cystadenocarcinoma
(55.2%
p
value
0.037
for
vs
70.25%,
0.08
PTX)
with
respect
free
form
drug.
fluorescent
nanosystems
were
significant
cell
uptake
after
few
hours
incubation
they
promoted
reduction
in
intracellular
reactive
oxygen
species.
results
need
be
validated
different
hHGS-OC
real
efficacy
proposed
nanomedicine
needs
investigated
using
vivo
models
carcinoma.
Cell Biology and Toxicology,
Journal Year:
2025,
Volume and Issue:
41(1)
Published: Jan. 14, 2025
Thyroid
cancer
(THCA)
is
an
increasingly
common
malignant
tumor
of
the
endocrine
system,
with
its
incidence
rising
steadily
in
recent
years.
For
patients
who
experience
recurrence
or
metastasis,
treatment
options
are
relatively
limited,
and
prognosis
poor.
Therefore,
exploring
new
therapeutic
strategies
has
become
particularly
urgent.
This
study
confirmed
that
effective
suppression
THCA
cell
proliferation
stimulation
apoptosis
can
be
achieved
through
application
Ginsenosides-Rh2.
Through
network
pharmacology
screening,
molecular
target
Ginsenosides-Rh2
was
identified
as
CHEK1,
inhibitory
effect
by
downregulating
CHEK1
protein
expression.
Furthermore,
demonstrations
conducted
both
vitro
vivo
showcased
delivering
using
nanoparticle
carriers
significantly
reduced
viability
approximately
50%,
regulated
DNA
damage
levels,
apoptosis-related
expression,
cycle
control.
The
IC50
formulation
determined
(B-CPAP
=
88.24
μM),
TPC
79.52
μM).
Cu2O@G-Rh2
suppressing
tumors
exhibits
a
significant
on
metastasis
while
maintaining
good
safety.
nanoparticles
possess
excellent
stability
anti-tumor
efficacy.
research
offers
perspectives
for
demonstrates
potential
clinical
applications.
